Tradestie Institutional Equity Comparison Engine

BCAX vs ANL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BCAX Overall Edge

BCAX Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bicara Therapeutics Inc. Common Stock (BCAX) driven by superior Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANL at N/M Forward P/E and -123.5% operating margin (+178.1% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BCAX N/M vs ANL N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin 0.0% vs -123.5% ยท YoY +0.0% vs +178.1%
Momentum & Technical Winner ANL
1Y -31.6% vs +564.2% ยท 52W Pos 8% vs 56%
Options & Structure Winner BCAX
BREAKDOWN (23rd %ile IV) vs UNCLASSIFIED (N/A IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
ANL US Equity
ANL
Institutional Equity
$10.03
-5.47% 1D
Market Cap $683.3M
1M Return -9.07%
1Y Return +564.24%
Forward P/E N/M
Unified AI Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -31.63% ANL +564.24% Spread: +595.87 pp (ANL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% ANL TTM Op. Margin: -123.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs ANL. Trailing 12-month operating profitability (BCAX 0.0% vs ANL -123.5%) and valuation multiples (BCAX N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (3) vs ANL (5)
Institutional Metric BCAX ANL Criterion Row Winner
Market Capitalization Scale $665.2M $683.3M Larger Scale ANL
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +178.1% Higher Growth ANL
Operating Margin (TTM) Profitability 0.0% -123.5% Higher Margin BCAX
Net Profit Margin Profitability 0.0% -124.8% Higher Margin BCAX
Return on Equity (ROE) Capital Efficiency -54.2% -20.2% Higher ROE ANL
52-Week Range Position Momentum 8% ($8โ€“$31) 56% ($1โ€“$17) Stronger Trend ANL
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 184% Vol 2.64ฮฒ ยท 81% Vol Lower Realized Risk ANL
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs ANL Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ANL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor ANL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.